CA2876995C — Novel selective pi3k delta inhibitors
Assigned to Rhizen Pharmaceuticals AG · Expires 2020-10-06 · 6y expired
What this patent protects
The present invention relates to selective inhibitors of PI3K delta protein kinases having a 1H-pyrazolo[3,4-d]pyrimidine ring system, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or …
USPTO Abstract
The present invention relates to selective inhibitors of PI3K delta protein kinases having a 1H-pyrazolo[3,4-d]pyrimidine ring system, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.